HC Wainwright reissued their buy rating on shares of Valneva (NASDAQ:VALN - Free Report) in a report released on Friday morning,Benzinga reports. The firm currently has a $17.00 target price on the stock.
Valneva Stock Performance
NASDAQ:VALN traded up $0.53 during trading hours on Friday, hitting $7.70. 20,406 shares of the company were exchanged, compared to its average volume of 26,031. The company's 50 day moving average price is $6.34 and its 200-day moving average price is $5.58. The stock has a market capitalization of $625.71 million, a price-to-earnings ratio of -59.23 and a beta of 1.93. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.
Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The firm had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. As a group, research analysts forecast that Valneva will post 0.13 earnings per share for the current year.
Institutional Trading of Valneva
An institutional investor recently raised its stake in Valneva stock. Wells Fargo & Company MN increased its holdings in shares of Valneva SE (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 246,766 shares of the company's stock after purchasing an additional 30,859 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.39% of the company's stock.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Read More
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
